Teva launches first inhalable antipsychotic drug in U.S.
Adasuve reduces agitation in adults with schizophrenia or bipolar I disorder.
Teva Pharmaceutical Industries is launching the first orally inhaled medicine for treating agitation associated with adult schizophrenia or bipolar I disorder in the United States, the company announced on Monday.
register with haaretz
Like us on Facebook and get articles directly in your news feed